Q: AVEO Oncology share price jumped after it got FDA approval for
FOTIVDA® (tivozanib) around 2 months ago. It ramped up for this by securing capital, and issued new equity, @ $ 8.00 which was fully subscribed, including all offered additional shares. New Director appointed who seems to be quite an authority on cancer research.
Unfortunately. the Share price dropped after the spike on approval, and has fallen back to old levels. what seems to be the problem ? When do you think, if at all, the price will reach the lofty levels recommended by the Analysts covering it.
Thanks and Appreciate all the advise and guidance you and your team provides.
Rajesh
FOTIVDA® (tivozanib) around 2 months ago. It ramped up for this by securing capital, and issued new equity, @ $ 8.00 which was fully subscribed, including all offered additional shares. New Director appointed who seems to be quite an authority on cancer research.
Unfortunately. the Share price dropped after the spike on approval, and has fallen back to old levels. what seems to be the problem ? When do you think, if at all, the price will reach the lofty levels recommended by the Analysts covering it.
Thanks and Appreciate all the advise and guidance you and your team provides.
Rajesh